NO313686B1 - Anvendelse av pentosanpolysulfat (PPS) for behandling av kroniske progressive vaskul¶re sykdommer - Google Patents

Anvendelse av pentosanpolysulfat (PPS) for behandling av kroniske progressive vaskul¶re sykdommer Download PDF

Info

Publication number: NO313686B1
Authority: NO; Norway
Prior art keywords: pps; disease; pharmaceutically acceptable; treatment; pps according
Prior art date: 1995-06-07

Application number

NO19973081A

Other languages

English (en)

Norwegian (no)

Other versions

NO973081D0 (no

NO973081L (no

Inventor

Gary E Striker

Liliane J Striker

Fred P Sherman

Original Assignee

Us Health

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-07

Filing date

1997-07-02

Publication date

2002-11-18

1997-07-02 Application filed by Us Health filed Critical Us Health

1997-07-02 Publication of NO973081D0 publication Critical patent/NO973081D0/no

1997-08-27 Publication of NO973081L publication Critical patent/NO973081L/no

2002-11-18 Publication of NO313686B1 publication Critical patent/NO313686B1/no

Links

229940043138 pentosan polysulfate Drugs 0.000 title claims abstract description 102
230000001684 chronic effect Effects 0.000 title claims abstract description 15
230000000750 progressive effect Effects 0.000 title claims abstract description 12
208000019553 vascular disease Diseases 0.000 title claims abstract description 12
238000011282 treatment Methods 0.000 title claims description 16
201000010099 disease Diseases 0.000 claims abstract description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
150000003839 salts Chemical class 0.000 claims abstract description 14
230000037390 scarring Effects 0.000 claims abstract description 9
230000003902 lesion Effects 0.000 claims abstract description 7
206010016654 Fibrosis Diseases 0.000 claims abstract description 4
230000004761 fibrosis Effects 0.000 claims abstract description 4
230000003176 fibrotic effect Effects 0.000 claims abstract description 4
239000003814 drug Substances 0.000 claims description 12
206010061989 glomerulosclerosis Diseases 0.000 claims description 11
239000002552 dosage form Substances 0.000 claims description 10
210000003734 kidney Anatomy 0.000 claims description 9
229940079593 drug Drugs 0.000 claims description 8
239000000203 mixture Substances 0.000 claims description 6
208000022461 Glomerular disease Diseases 0.000 claims description 5
206010012601 diabetes mellitus Diseases 0.000 claims description 5
231100000852 glomerular disease Toxicity 0.000 claims description 5
239000003826 tablet Substances 0.000 claims description 5
239000004480 active ingredient Substances 0.000 claims description 4
239000004615 ingredient Substances 0.000 claims description 4
201000006370 kidney failure Diseases 0.000 claims description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
239000006186 oral dosage form Substances 0.000 claims description 4
239000000546 pharmaceutical excipient Substances 0.000 claims description 4
230000002792 vascular Effects 0.000 claims description 4
206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
208000031481 Pathologic Constriction Diseases 0.000 claims description 3
239000002775 capsule Substances 0.000 claims description 3
208000020832 chronic kidney disease Diseases 0.000 claims description 3
208000028208 end stage renal disease Diseases 0.000 claims description 3
201000000523 end stage renal failure Diseases 0.000 claims description 3
239000000945 filler Substances 0.000 claims description 3
238000001631 haemodialysis Methods 0.000 claims description 3
230000000322 hemodialysis Effects 0.000 claims description 3
210000000056 organ Anatomy 0.000 claims description 3
159000000000 sodium salts Chemical group 0.000 claims description 3
230000036262 stenosis Effects 0.000 claims description 3
208000037804 stenosis Diseases 0.000 claims description 3
238000001356 surgical procedure Methods 0.000 claims description 3
238000002054 transplantation Methods 0.000 claims description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
239000011230 binding agent Substances 0.000 claims description 2
210000004204 blood vessel Anatomy 0.000 claims description 2
239000007903 gelatin capsule Substances 0.000 claims description 2
239000007788 liquid Substances 0.000 claims description 2
239000007937 lozenge Substances 0.000 claims description 2
235000019359 magnesium stearate Nutrition 0.000 claims description 2
239000008108 microcrystalline cellulose Substances 0.000 claims description 2
229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
239000006187 pill Substances 0.000 claims description 2
230000000306 recurrent effect Effects 0.000 claims description 2
239000011734 sodium Substances 0.000 claims description 2
229910052708 sodium Inorganic materials 0.000 claims description 2
239000002904 solvent Substances 0.000 claims description 2
210000003934 vacuole Anatomy 0.000 claims description 2
208000017667 Chronic Disease Diseases 0.000 claims 1
235000015424 sodium Nutrition 0.000 claims 1
239000007939 sustained release tablet Substances 0.000 claims 1
238000000034 method Methods 0.000 abstract description 11
239000008194 pharmaceutical composition Substances 0.000 abstract description 5
208000032544 Cicatrix Diseases 0.000 abstract description 3
231100000241 scar Toxicity 0.000 abstract description 3
230000037387 scars Effects 0.000 abstract description 3
238000004090 dissolution Methods 0.000 abstract description 2
102000008186 Collagen Human genes 0.000 description 28
108010035532 Collagen Proteins 0.000 description 28
229920001436 collagen Polymers 0.000 description 26
108020004999 messenger RNA Proteins 0.000 description 26
210000004027 cell Anatomy 0.000 description 19
238000003752 polymerase chain reaction Methods 0.000 description 15
230000002860 competitive effect Effects 0.000 description 12
239000002299 complementary DNA Substances 0.000 description 12
229920000669 heparin Polymers 0.000 description 12
229960002897 heparin Drugs 0.000 description 12
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 11
241000699670 Mus sp. Species 0.000 description 10
230000000694 effects Effects 0.000 description 10
230000002829 reductive effect Effects 0.000 description 8
241000699660 Mus musculus Species 0.000 description 7
239000003651 drinking water Substances 0.000 description 7
235000020188 drinking water Nutrition 0.000 description 7
210000003584 mesangial cell Anatomy 0.000 description 7
238000011830 transgenic mouse model Methods 0.000 description 7
102000029816 Collagenase Human genes 0.000 description 6
108060005980 Collagenase Proteins 0.000 description 6
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
239000003102 growth factor Substances 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 5
208000034189 Sclerosis Diseases 0.000 description 5
230000035508 accumulation Effects 0.000 description 5
238000009825 accumulation Methods 0.000 description 5
230000001434 glomerular Effects 0.000 description 5
238000010839 reverse transcription Methods 0.000 description 5
238000012360 testing method Methods 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
102000007469 Actins Human genes 0.000 description 4
108010085238 Actins Proteins 0.000 description 4
206010020772 Hypertension Diseases 0.000 description 4
102000005741 Metalloproteases Human genes 0.000 description 4
108010006035 Metalloproteases Proteins 0.000 description 4
230000010261 cell growth Effects 0.000 description 4
230000004663 cell proliferation Effects 0.000 description 4
229960002424 collagenase Drugs 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000000499 gel Substances 0.000 description 4
201000008350 membranous glomerulonephritis Diseases 0.000 description 4
238000013059 nephrectomy Methods 0.000 description 4
238000011002 quantification Methods 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
210000000329 smooth muscle myocyte Anatomy 0.000 description 4
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
102000004266 Collagen Type IV Human genes 0.000 description 3
108010042086 Collagen Type IV Proteins 0.000 description 3
238000012408 PCR amplification Methods 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
238000011534 incubation Methods 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
229940104230 thymidine Drugs 0.000 description 3
230000004544 DNA amplification Effects 0.000 description 2
208000007342 Diabetic Nephropathies Diseases 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
102000012750 Membrane Glycoproteins Human genes 0.000 description 2
108010090054 Membrane Glycoproteins Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
238000010222 PCR analysis Methods 0.000 description 2
239000012807 PCR reagent Substances 0.000 description 2
208000006265 Renal cell carcinoma Diseases 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
238000012197 amplification kit Methods 0.000 description 2
239000007640 basal medium Substances 0.000 description 2
210000002469 basement membrane Anatomy 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
108010006025 bovine growth hormone Proteins 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
210000002808 connective tissue Anatomy 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
208000033679 diabetic kidney disease Diseases 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
229960005542 ethidium bromide Drugs 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000002955 isolation Methods 0.000 description 2
238000002372 labelling Methods 0.000 description 2
231100000053 low toxicity Toxicity 0.000 description 2
239000000463 material Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
239000000178 monomer Substances 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000008177 pharmaceutical agent Substances 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
150000004804 polysaccharides Chemical class 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
239000003161 ribonuclease inhibitor Substances 0.000 description 2
230000002784 sclerotic effect Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
-1 vanadyl ribonucleoside Chemical compound 0.000 description 2
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 description 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
238000010600 3H thymidine incorporation assay Methods 0.000 description 1
DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
102000012422 Collagen Type I Human genes 0.000 description 1
108010022452 Collagen Type I Proteins 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
206010051055 Deep vein thrombosis Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
241001070947 Fagus Species 0.000 description 1
229920001499 Heparinoid Polymers 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
208000005615 Interstitial Cystitis Diseases 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
101001075372 Mus musculus Gamma-glutamyl hydrolase Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
102100037968 Ribonuclease inhibitor Human genes 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
102000007000 Tenascin Human genes 0.000 description 1
108010008125 Tenascin Proteins 0.000 description 1
108010000499 Thromboplastin Proteins 0.000 description 1
102100030859 Tissue factor Human genes 0.000 description 1
102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
206010047249 Venous thrombosis Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
PYMYPHUHKUWMLA-VPENINKCSA-N aldehydo-D-xylose Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-VPENINKCSA-N 0.000 description 1
229930094280 aldehydo-D-xylose Natural products 0.000 description 1
150000001412 amines Chemical group 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
230000000964 angiostatic effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000001736 capillary Anatomy 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
235000013869 carnauba wax Nutrition 0.000 description 1
239000004203 carnauba wax Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
239000004927 clay Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000011382 collagen catabolic process Effects 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
210000005257 cortical tissue Anatomy 0.000 description 1
MSJQCBORNZDNDU-UHFFFAOYSA-D decasodium 3-methoxy-6-[2-(6-methoxy-4,5-disulfonatooxyoxan-3-yl)oxy-5-[5-(5-methoxy-3,4-disulfonatooxyoxan-2-yl)oxy-3,4-disulfonatooxyoxan-2-yl]oxy-4-sulfonatooxyoxan-3-yl]oxy-4,5-disulfonatooxyoxane-2-carboxylate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].COC1COC(OC2COC(OC3COC(OC4COC(OC)C(OS([O-])(=O)=O)C4OS([O-])(=O)=O)C(OC4OC(C(OC)C(OS([O-])(=O)=O)C4OS([O-])(=O)=O)C([O-])=O)C3OS([O-])(=O)=O)C(OS([O-])(=O)=O)C2OS([O-])(=O)=O)C(OS([O-])(=O)=O)C1OS([O-])(=O)=O MSJQCBORNZDNDU-UHFFFAOYSA-D 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000000326 densiometry Methods 0.000 description 1
238000000151 deposition Methods 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000002222 downregulating effect Effects 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
229940043249 elmiron Drugs 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 1
238000013265 extended release Methods 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
239000000834 fixative Substances 0.000 description 1
210000003904 glomerular cell Anatomy 0.000 description 1
150000002302 glucosamines Chemical class 0.000 description 1
150000004676 glycans Polymers 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
239000002554 heparinoid Substances 0.000 description 1
229940025770 heparinoids Drugs 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
238000010820 immunofluorescence microscopy Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
229940060367 inert ingredients Drugs 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
235000013372 meat Nutrition 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
238000001531 micro-dissection Methods 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
108700039855 mouse a Proteins 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000035778 pathophysiological process Effects 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
108010024226 placental ribonuclease inhibitor Proteins 0.000 description 1
230000007505 plaque formation Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
208000037821 progressive disease Diseases 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
150000003214 pyranose derivatives Chemical group 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
201000010174 renal carcinoma Diseases 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000002342 ribonucleoside Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
241000894007 species Species 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000019635 sulfation Effects 0.000 description 1
238000005670 sulfation reaction Methods 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
230000008364 tissue synthesis Effects 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
238000012762 unpaired Student’s t-test Methods 0.000 description 1
208000019206 urinary tract infection Diseases 0.000 description 1
230000004218 vascular function Effects 0.000 description 1
210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000001993 wax Substances 0.000 description 1
229920001221 xylan Polymers 0.000 description 1
150000004823 xylans Chemical class 0.000 description 1
238000007805 zymography Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO19973081A 1995-06-07 1997-07-02 Anvendelse av pentosanpolysulfat (PPS) for behandling av kroniske progressive vaskul¶re sykdommer NO313686B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/478,347 US5643892A (en)	1995-06-07	1995-06-07	Method of treating chronic progressive vascular diseases
PCT/US1996/008367 WO1996040158A1 (en)	1995-06-07	1996-06-03	Method of treating chronic progressive vascular diseases
BR9704114-9A BR9704114A (pt)	1995-06-07	1997-07-28	Processo de tratamento de doenças vasculares progressivas crÈnicas

Publications (3)

Publication Number	Publication Date
NO973081D0 NO973081D0 (no)	1997-07-02
NO973081L NO973081L (no)	1997-08-27
NO313686B1 true NO313686B1 (no)	2002-11-18

Family

ID=25664870

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19973081A NO313686B1 (no)	1995-06-07	1997-07-02	Anvendelse av pentosanpolysulfat (PPS) for behandling av kroniske progressive vaskul¶re sykdommer

Country Status (14)

Country	Link
US (1)	US5643892A (es)
EP (1)	EP0809505B1 (es)
AU (1)	AU699012B2 (es)
BR (1)	BR9704114A (es)
CA (1)	CA2210351C (es)
DE (1)	DE809505T1 (es)
ES (1)	ES2115571T3 (es)
HU (1)	HUP9802431A3 (es)
IL (1)	IL121217A (es)
NO (1)	NO313686B1 (es)
NZ (1)	NZ309991A (es)
TW (1)	TW434018B (es)
WO (1)	WO1996040158A1 (es)
ZA (1)	ZA964247B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20010005720A1 (en) *	1995-06-07	2001-06-28	U.S.A. As Represented By The Secretary Department Of Health And Human Services	Method of treating chronic progressive vascular scarring diseases
US6255295B1 (en)	1996-12-23	2001-07-03	Nutramax Laboratories, Inc.	Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine composition for the protection, treatment, repair, and reduction of inflammation of connective tissue
UA65587C2 (en) *	1997-10-09	2004-04-15	Baker Norton Pharma	Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus
DE19747195A1 (de) *	1997-10-24	1999-04-29	Knoll Ag	Verwendung von Glykosaminoglykanen zur Herstellung von pharmazeutischen Zubereitungen zur Behandlung von mit Diabetes assoziierten Augenkrankheiten
AU2001230994A1 (en) *	2000-01-19	2001-07-31	The United States of America, represented by The Secretary, Department of Health & Human Services	Use of pentosan polysulfate to treat certain conditions of the prostate
CA2616230A1 (en) *	2005-07-22	2007-02-01	Trf Pharma, Inc.	Method for treating sickle cell disease and sickle cell disease sequelae
DK2010220T3 (da) *	2006-04-03	2022-05-23	Ceva Animal Health Pty Ltd	Stabiliserede pentosanpolysulfat-(pps)-formuleringer
EP2407174B1 (en)	2009-03-11	2014-05-07	Jellice Co., Ltd.	Progression inhibitor or prophylactic agent for atherosclerosis, blood cholesterol level-lowering agent, and functional food or food for specified health uses
WO2011088418A2 (en) *	2010-01-15	2011-07-21	Mount Sinai School Of Medicine	Inhibition of tnf-alpha induced activation of nfkb by pentosan polysulfate
JP6175431B2 (ja)	2011-06-20	2017-08-02	アイカーンスクールオブメディシンアットマウントサイナイ	ムコ多糖症およびその他のリソソーム障害に対する抗ｔｎｆ療法
US20130273096A1 (en) *	2011-10-05	2013-10-17	Bruce A. Daniels	Therapeutic Sulfated Polysaccharides, Compositions Thereof, and Methods for Treating Patients
WO2020039480A1 (ja)	2018-08-20	2020-02-27	株式会社レクメド	新規ポリ硫酸ペントサンナトリウム製剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4966890A (en) *	1986-04-04	1990-10-30	Angiogenics, Ltd.	Method and composition for arresting angiogenesis and capillary, cell or membrane leakage
US4820693A (en) *	1986-05-22	1989-04-11	Angiogenics, Ltd.	Method and composition for arresting angiogenesis and capillary, cell or membrane leakage
DE3725554A1 (de) *	1987-08-01	1989-02-09	Hoechst Ag	Pharmazeutisches kombinationspraeparat sowie dessen herstellung und verwendung
US5032679A (en) *	1988-12-15	1991-07-16	Glycomed, Inc.	Heparin fragments as inhibitors of smooth muscle cell proliferation
EP0466315A3 (en) *	1990-05-30	1992-07-01	Larrian Gillespie	Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation
US5605938A (en) *	1991-05-31	1997-02-25	Gliatech, Inc.	Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate

1995
- 1995-06-07 US US08/478,347 patent/US5643892A/en not_active Expired - Fee Related
1996
- 1996-05-27 ZA ZA964247A patent/ZA964247B/xx unknown
- 1996-06-03 WO PCT/US1996/008367 patent/WO1996040158A1/en not_active Ceased
- 1996-06-03 HU HU9802431A patent/HUP9802431A3/hu unknown
- 1996-06-03 AU AU60300/96A patent/AU699012B2/en not_active Ceased
- 1996-06-03 EP EP96917917A patent/EP0809505B1/en not_active Expired - Lifetime
- 1996-06-03 ES ES96917917T patent/ES2115571T3/es not_active Expired - Lifetime
- 1996-06-03 IL IL12121796A patent/IL121217A/xx not_active IP Right Cessation
- 1996-06-03 NZ NZ309991A patent/NZ309991A/en unknown
- 1996-06-03 DE DE0809505T patent/DE809505T1/de active Pending
- 1996-06-03 CA CA002210351A patent/CA2210351C/en not_active Expired - Fee Related
- 1996-08-03 TW TW085109390A patent/TW434018B/zh not_active IP Right Cessation
1997
- 1997-07-02 NO NO19973081A patent/NO313686B1/no unknown
- 1997-07-28 BR BR9704114-9A patent/BR9704114A/pt not_active Application Discontinuation

Also Published As

Publication number	Publication date
US5643892A (en)	1997-07-01
EP0809505A4 (en)	1998-07-01
NO973081D0 (no)	1997-07-02
BR9704114A (pt)	2000-06-06
IL121217A0 (en)	1999-10-28
ES2115571T3 (es)	2003-09-01
AU6030096A (en)	1996-12-30
ES2115571T1 (es)	1998-07-01
WO1996040158A1 (en)	1996-12-19
CA2210351A1 (en)	1996-12-19
NO973081L (no)	1997-08-27
NZ309991A (en)	2001-03-30
ZA964247B (en)	1996-12-04
EP0809505A1 (en)	1997-12-03
CA2210351C (en)	2003-09-23
TW434018B (en)	2001-05-16
HUP9802431A3 (en)	2001-06-28
AU699012B2 (en)	1998-11-19
IL121217A (en)	2000-09-28
HUP9802431A2 (hu)	1999-02-01
DE809505T1 (de)	1998-05-28
EP0809505B1 (en)	2003-04-02

Publication	Publication Date	Title
Yang et al.	2022	Effects and mechanisms of SGLT2 inhibitors on the NLRP3 inflammasome, with a focus on atherosclerosis
NO313686B1 (no)	2002-11-18	Anvendelse av pentosanpolysulfat (PPS) for behandling av kroniske progressive vaskul¶re sykdommer
US20150196580A1 (en)	2015-07-16	Use of defibrotide for the inhibition of heparanase
US9107885B2 (en)	2015-08-18	PRG4 treatment for interstitial cystitis
Chang et al.	2021	Inhibition on CXCL5 reduces aortic matrix metalloproteinase 9 expression and protects against acute aortic dissection
AU750182B2 (en)	2002-07-11	Method of treating chronic progressive vascular scarring diseases
US7645733B2 (en)	2010-01-12	Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
Cui et al.	2021	Minocycline attenuates oxidative and inflammatory injury in a intestinal perforation induced septic lung injury model via down-regulating lncRNA MALAT1 expression
WO2021073249A1 (zh)	2021-04-22	β-NMN在制备脓毒症器官损伤的治疗、预防药物中的应用
KR20210108326A (ko)	2021-09-02	Lin28a 유전자 또는 단백질을 포함하는 만성신장질환 또는 신장섬유화질환 예방, 개선 또는 치료용 조성물
RU2196589C2 (ru)	2003-01-20	Способ индукции рассасывания образовавшихся рубцов или фиброзных образований в кровеносных сосудах или в сосудистой сети млекопитающего
HK1005497B (en)	2003-12-24	Use of pentosan polysulfate for the resolution of scars in chronic progressive vascular diseases
CN101879151A (zh)	2010-11-10	大黄素在制备p2x3介导神经病理痛/神经系统疾病药物中的应用
CN108948158B (zh)	2021-06-15	四连接素模拟肽tnp及其应用
MXPA99009415A (es)	2000-07-01	Metodo de tratamiento para enfermedades de cicatrizacion vascular progresivas, cronicas
Samad et al.	2025	Cilostazol or canagliflozin mitigates Cyclosporine A-induced nephrotoxicity by modulating the STAMP2-mTOR-AMPK signaling pathway and autophagy in a rat model
Dobrowolski et al.	2023	Vasoprotective Effect of Sulodexide in Diabetic Retinopathy
WO2024012531A1 (zh)	2024-01-18	一种吡啶酮衍生物的应用
CN119745887A (zh)	2025-04-04	小分子激动剂tepp-46在制备预防和/或治疗主动脉瘤及相关心血管疾病的药物中的应用
CN119548486A (zh)	2025-03-04	他米巴罗汀在医学中的新应用
HK1027970A (en)	2001-02-02	Method of treating chronic progressive vascular scarring diseases
WO2012106287A2 (en)	2012-08-09	Methods of treating acute kidney injury with retinoc acid